Loading...
XASENBY
Market cap2mUSD
Dec 23, Last price  
0.52USD
1D
-2.49%
1Q
-26.71%
Jan 2017
-99.55%
IPO
-99.98%
Name

NovaBay Pharmaceuticals Inc

Chart & Performance

D1W1MN
XASE:NBY chart
P/E
—
P/S
0.17
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-24.39%
Rev. gr., 5y
3.32%
Revenues
15m
+2.24%
001,533,0005,913,0006,722,00015,684,0009,754,00011,019,0006,947,0003,477,0001,054,0004,381,00011,897,00018,230,00012,508,0006,599,0009,934,0008,421,00014,404,00014,726,000
Net income
-10m
L-40.73%
-2,804,000-3,463,000-5,286,000-5,400,000-8,114,0002,697,000-4,308,000-5,085,000-7,027,000-16,042,000-15,194,000-18,973,000-13,151,000-7,403,000-6,545,000-10,487,000-11,039,000-6,559,000-16,265,000-9,640,000
CFO
-4m
L-37.92%
-3,230,0004,744,000-6,271,000-9,942,000-1,648,0002,028,000-3,142,000-6,528,000-12,969,000-15,055,000-18,559,000-12,135,000-6,270,000-5,568,000-7,929,000-4,721,000-9,192,000-6,654,000-4,131,000
Earnings
Mar 24, 2025

Profile

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
URL
https://novabay.com/
IPO date
Oct 26, 2007
Employees
29
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
14,726
2.24%
14,404
71.05%
8,421
-15.23%
Cost of revenue
19,729
22,084
17,283
Unusual Expense (Income)
NOPBT
(5,003)
(7,680)
(8,862)
NOPBT Margin
Operating Taxes
(3,809)
(4,615)
Tax Rate
NOPAT
(5,003)
(3,871)
(4,247)
Net income
(9,640)
-40.73%
(16,265)
147.98%
(6,559)
-40.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,565
4,738
16,684
BB yield
-14,511.03%
-150.92%
-101.50%
Debt
Debt current
2,127
453
305
Long-term debt
2,711
3,629
692
Deferred revenue
Other long-term liabilities
334
10,119
Net debt
1,708
(1,764)
(6,982)
Cash flow
Cash from operating activities
(4,131)
(6,654)
(9,192)
CAPEX
(19)
(112)
(52)
Cash from investing activities
(19)
(112)
(12,045)
Cash from financing activities
1,910
4,633
16,789
FCF
(4,590)
(5,041)
(6,226)
Balance
Cash
3,130
5,362
7,504
Long term investments
484
475
Excess cash
2,394
5,126
7,558
Stockholders' equity
(172,787)
(154,527)
(140,729)
Invested Capital
179,670
167,122
161,570
ROIC
ROCE
EV
Common stock shares outstanding
120
1,610
1,247
Price
0.20
-89.54%
1.95
-85.21%
13.18
-45.97%
Market cap
25
-99.22%
3,140
-80.90%
16,437
-32.77%
EV
3,683
4,348
10,135
EBITDA
(4,800)
(7,197)
(8,743)
EV/EBITDA
Interest
3,809
Interest/NOPBT